Program Summary
CLL today: accomplishments, main research areas, key pending issues
Clonal evolution and therapy resistance
Microenvironment and signalling in the evolution of the disease
Inmunotherapy in CLL: where we are, biological and clinical update
Front line therapy
Residual measurable disease
Side effects of new therapeutic agents
Beyond the first line: therapy selection in the era of targeted therapies
New therapies and therapeutic approaches
Mechanisms of resistance
Recent molecular findings, important for prognosis estimation
Ongoing Laboratory research in the region (2 sessions)
Round table on: 1) Clinical Trial Experience in 3 Latin American Countries 2) CLL registries
Case presentations to experts
Poster session/ wine & cheese evening. Oral presentation of selected posters
4 early bird morning sessions (2 laboratory, 2 clinical)
3 farmaceutical company symposia